Patent EA-005128-B1 (EA)
Title: Diphenylurea compounds, a process for their preparation and pharmaceutical composition containing them
Inventor: LAVIELLE GILBERT
IPC: C07D401/04
Filed: 2001-06-28
Abstract: 1. A compound selected from those of formula (I): wherein R1, R2, R3 and R4 independently represent hydrogen, halogen or alkyl, alkoxy, hydroxy, alkylthio, mercapto, cyano, amino (optionally substituted by one or two alkyl), nitro, carboxy, alkoxycarbonyl, aminocarbonyl (optionally substituted by one or two alkyl) or carbamoyl, or, taken in pairs, form together with the carbon atoms to which they are bonded a phenyl ring or an aromatic heterocycle having from 5 to 7 ring members and containing from 1 to 3 hetero atoms selected from nitrogen, oxygen and sulphur, L1 and L2 each represents hydrogen or together form -CH2-CH2-, X1, attached at the 2 or 3 position of the aromatic ring, represents a bond, and in that case X2 represents hydrogen, halogen, alkyl, alkoxy, hydroxy, nitro or cyano, or amino (optionally substituted by one or two alkyl), or, X1 and X2, together with two adjacent carbon to which they are bonded in the 2, 3 or 4 position of the aromatic ring, form (C4-C7)cycloalkyl wherein one or two -CH2- of the cycloalkyl ring are optionally replaced by oxygen or NH (optionally substituted by alkyl) and wherein one carbon of the cycloalkyl ring is substituted by G, X3 represents hydrogen, halogen, alkyl, alkoxy, hydroxy, nitro or cyano, or amino (optionally substituted by one or two alkyl), G represents a group selected from: wherein: the broken lines indicate the optional presence of a double bond, Alk represents linear or branched (C1-C6)alkylene wherein, when G1 or G2 contains imidazoline, the group Alk- is attached at the 2 position of the ring, n is 0 or 1, T3 represents alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl, T4 represents alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl, wherein: the term "alkyl" denotes linear or branched group containing from 1 to 6 carbon, the term "alkoxy" denotes linear or branched alkyl-oxy containing from 1 to 6 carbon, the term "aryl" denotes phenyl, naphthyl or biphenyl, the term "heteroaryl" denotes an aromatic monocyclic group, or a bicyclic group in which at least one of the rings is aromatic, each group containing from 5 to 11 ring members and from 1 to 5 hetero atoms selected from nitrogen, oxygen and sulphur, the expression "optionally substituted" associated with aryl, arylalkyl, heteroaryl and heteroarylalkyl denotes that those groups are unsubstituted or substituted on the cyclic moiety by one or more halogen and/or alkyl, alkoxy, hydroxy, mercapto, alkylthio, cyano, amino (optionally substituted by one or two alkyl), nitro, carboxy, alkoxycarbonyl, aminocarbonyl (optionally substituted by one or two alkyl) or carbamoyl, wherein heteroaryl and heteroarylalkyl may in addition be substituted by oxo, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 2. Compounds of claim 1, wherein L1 and L2 each represents hydrogen, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 3. Compounds of claim 1, wherein L1 and L2 together form -CH2-CH2-, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 4. Compounds of claim 1, wherein R1 and R4 each represents hydrogen, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 5. Compounds of claim 1, wherein R2 and R3 are selected from halogen and alkyl, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 6. Compounds of claim 1, wherein X1 is attached at the 2 position of the phenyl ring, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 7. Compounds of claim 1, wherein X1 represents a bond and X2 represents halogen or alkyl or alkoxy, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 8. Compounds of claim 1, wherein X3 represents hydrogen, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 9. Compounds of claim 1, wherein R3 and R4 together with carbon to which they are bonded form a phenyl ring and L1 and L2 together form -CH2-CH2-, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 10. Compounds of claim 1, wherein G is selected from: wherein T'3 will be more especially optionally substituted heteroaryl or optionally substituted heteroarylalkyl, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 11. Compounds of claim 1, wherein X1 and X2, together with two carbon in the 2 and 3 position of the aromatic ring to which they are bonded, form (C4-C7)cycloalkyl, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 12. Compound of formula (I) that is N-(3-chloro-4-methylphenyl)-N'-{3-[4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-1-piperazinyl]phenyl}urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 13. Compound of formula (I) that is N-[4-chloro-3-(4,5-dihydro-1H-imidazol-2-ylamino) phenyl]-N'-(3-chloro-4-methylphenyl)urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 14. Compound of formula (I) that is N-(3-chloro-4-methylphenyl)-N'-[2-(1H-imidazol-4-yl)-indan-5-yl]urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 15. Compound of formula (I) that is N-{3-[4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-1-piperazinyl]phenyl}-N'-(3,4-dimethylphenyl)urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base. 16. Process for the preparation of the compounds of formula (I) according to claim 1, characterised in that there is used as starting material an aromatic amine of formula (II): wherein X1, X2, X3 and G are as defined for formula (I), which is condensed by heating in basic medium with a compound of formula (III): wherein R1, R2, R3 and R4 are as defined for formula (I), to yield the compound of formula (I/a): a particular case of the compounds of formula (I) wherein R1, R2 R3, R4, X1, X2, X3 and G are as defined hereinbefore, wherein the isocyanate of formula (III) is either commercially available or is prepared according to known procedures, which compounds of formula (I/a) - may, if necessary, be purified according to a conventional purification technique, - are optionally separated into isomers according to a conventional separation technique, - are, if desired, converted into addition salts with a pharmaceutically acceptable acid or base. 17. Process for the preparation of the compounds of formula (I) according to claim 1, characterised in that there is used as starting material an amine of formula (IV): wherein L1, L2, R1, R2, R3 and R4 are as defined for formula (I), which is condensed by heating in basic medium with a compound of formula (V): wherein X1, X2, X3 and G are as defined for formula (I), to yield the compound of formula (I/b): a particular case of the compounds of formula (I) wherein R1, R2 R3, R4, L1, L2, X1, X2, X3 and G are as defined hereinbefore, wherein the isocyanate of formula (V) is either commercially available or is prepared according to known procedures, which compounds of formula (I/b) - may, if necessary, be purified according to a conventional purification technique, - are optionally separated into isomers according to a conventional separation technique, - are, if desired, converted into addition salts with a pharmaceutically acceptable acid or base. 18. Process for the preparation of the compounds of formula (I) according to claim 1, characterised in that there is used as starting material an amine of formula (VI): wherein X1, X2 and X3 are as defined for formula (I), GN34 represents an NH group piperidinyl group, and P represents a hydrogen atom or a group protecting the amine function, which is condensed by heating in basic medium with a compound of formula (III): wherein R1, R2, R3 and R4 are as defined for formula (I), to yield the compound of formula (VII): wherein R1, R2 R3, R4, X1, X2, X3, GN34 and P are as defined hereinbefore, which compound of formula (VII), after deprotection where necessary, is condensed with thiophosgene to yield the compound of formula (VIII): wherein R1, R2 R3, R4, X1, X2 and X3 are as defined hereinbefore, which is subjected to the action of ethylenediamine to yield the compound of formula (IX): wherein R1, R2 R3, R4, X1, X2 and X3 are as defined hereinbefore, which compound of formula (IX) is subjected to an intramolecular cyclisation reaction catalysed by a palladium compound to yield the compound of formula (I/d): a particular case of the compounds of formula (I) wherein R1, R2 R3, R4, X1, X2 and X3 are as defined hereinbefore, which compounds of formula (I/d), - may, if necessary, be purified according to a conventional purification technique, - are optionally separated into isomers according to a conventional separation technique, - are converted, if desired, into addition salts with a pharmaceutically acceptable acid or base. 19. Pharmaceutical compositions comprising as active ingredient at least one compound according to any one of claims 1 to 15, alone or in combination with one or more pharmaceutically acceptable, inert, non-toxic excipients or carriers. 20. Pharmaceutical compositions according t